Analysts Issue Forecasts for Oncobiologics FY2026 Earnings

Oncobiologics, Inc. (NASDAQ:OTLK) – Analysts at Brookline Capital Markets upped their FY2026 EPS estimates for shares of Oncobiologics in a report released on Tuesday, August 18th. Brookline Capital Markets analyst K. Dolliver now expects that the company will earn ($0.42) per share for the year, up from their previous estimate of ($0.50). The consensus estimate for Oncobiologics’ current full-year earnings is ($0.49) per share. Brookline Capital Markets also issued estimates for Oncobiologics’ Q4 2026 earnings at ($0.07) EPS, Q4 2027 earnings at $0.05 EPS and FY2027 earnings at ($0.06) EPS.

Oncobiologics (NASDAQ:OTLK) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.97 million.

OTLK has been the subject of a number of other research reports. Wall Street Zen cut Oncobiologics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Ascendiant Capital Markets raised their price target on Oncobiologics from $6.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, June 11th. BTIG Research reaffirmed a “buy” rating and set a $4.00 price objective on shares of Oncobiologics in a research note on Friday, August 14th. Weiss Ratings upgraded Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 12th. Finally, HC Wainwright upped their price target on shares of Oncobiologics to $1.60 and gave the stock a “neutral” rating in a report on Monday, July 27th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Oncobiologics currently has a consensus rating of “Hold” and an average price target of $4.65.

Oncobiologics Price Performance

Shares of NASDAQ OTLK opened at $0.68 on Friday. Oncobiologics has a 1-year low of $0.16 and a 1-year high of $3.39. The business’s 50 day moving average is $1.30 and its two-hundred day moving average is $0.71. The stock has a market capitalization of $100.49 million, a P/E ratio of -0.88 and a beta of 0.82.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. raised its stake in shares of Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after acquiring an additional 21,941 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Oncobiologics by 74.1% during the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after acquiring an additional 44,063 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after acquiring an additional 25,351 shares in the last quarter. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Insider Transactions at Oncobiologics

In related news, Director Ghiath M. Sukhtian acquired 2,525,252 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were bought at an average price of $0.99 per share, with a total value of $2,499,999.48. Following the completion of the transaction, the director directly owned 24,617,320 shares in the company, valued at $24,371,146.80. This trade represents a 11.43% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Faisal Ghiath Sukhtian bought 95,398 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was bought at an average price of $1.05 per share, for a total transaction of $100,167.90. Following the purchase, the director directly owned 220,972 shares of the company’s stock, valued at $232,020.60. The trade was a 75.97% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 11,189,359 shares of company stock worth $7,662,666. 1.80% of the stock is owned by corporate insiders.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.